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Objective: To highlight which demographic, familial, premorbid, clinical, therapeutic, 
 rehabilitative, and assistance factors were related to dual diagnosis, which, in psychiatry, means 
the co-occurrence of both mental disorder and substance use in the same patient.
Methods: Our sample (N=145) was chosen from all outpatients with a dual diagnosis treated 
from January 1, 2012 to July 31, 2012 by both the Mental Health Service and the Substance 
Use Service of Modena and Castelfranco Emilia, Italy. Patients who dropped out during the 
study period were excluded. Demographic data and variables related to familial and premorbid 
history, clinical course, rehabilitative programs, social support and nursing care, and outcome 
complications were collected. The patients’ clinical and functioning conditions during the study 
period were evaluated.
Results: Our patients were mostly men suffering from a cluster B personality disorder. Sub-
stance use was significantly more likely to precede psychiatric disease (P0.001), and 60% of 
the sample presented a positive familial history for psychiatric or addiction disease or premor-
bid traumatic factors. The onset age of substance use was related to the period of psychiatric 
treatment follow-up (P0.001) and the time spent in rehabilitative facilities (P0.05), which, 
in turn, was correlated with personality disorder diagnosis (P0.05). Complications, which 
presented in 67% of patients, were related to the high number of psychiatric hospitalizations 
(P0.05) and professionals involved in each patient’s treatment (P0.05). Males more fre-
quently presented familial, health, and social complications, whereas females more frequently 
presented self-threatening behavior (P0.005). 
Conclusion: It was concluded that the course of dual diagnosis may be chronic, severe, and 
disabling, requiring many long-term therapeutic and rehabilitative programs to manage vari-
ous disabilities.
Keywords: dual diagnosis patients, mental health and substance use services, mental disorder 
and substance use co-occurrence
Introduction 
In psychiatry, the term “dual diagnosis” and other interchangeable terms (eg, comor-
bidity, co-occurring illnesses, concurrent disorders, dual disorder, double trouble) 
mean the co-occurrence of both a mental health disorder and substance use in the same 
patient.1,2 The occurrence of dual diagnosis is quite common: Regier et al3 reported 
that 44% of alcohol abusers and 64.4% of illegal substance abusers suffered from a 
major mental disorder, whereas Kessler et al4,5 found that persons affected by alcohol 
or illegal drug dependence presented a mental disorder 4.1 times and 4.9 times more 
frequently, respectively, than non–alcohol-dependent people.
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Other studies have shown that 56% of patients suffering 
from a substance use disorder had a mental disorder at the 
same time6 and that from 18.5% to 50.0% of patients with 
a substance use disorder had received psychiatric treatment 
during their lifetimes.7–9 
Among dual-diagnosis patients, substance-use disorders 
range from single drug abuse to cocktails of substances, 
whereas mental health problems include both a wide range 
of disorders, from those defined as “high-prevalence and low-
impact therapeutic”, such as anxiety and depression, to those 
defined as “low prevalence, high-impact therapeutic”, such 
as psychosis and major mood disorders. Although the “low 
impact” group is the most represented among dual-diagnosis 
patients, the “high impact” group, even if smaller, requires 
more intensive and expensive treatment programs.10 The 
co-occurrence of the abovementioned disorders increases 
the severity of symptoms and difficulty of treatment, with 
worse physical, psychological, and social outcomes.10 The 
clinical and rehabilitative needs of dual-diagnosis patients 
can be extremely different and polymorphic, depending on 
the level of their functioning, which is usually conditioned by 
pathological behavior and poor therapeutic compliance.11,12
Neurobiological models attribute the key role in the devel-
opment of addiction to the brain’s reward system via the dop-
aminergic mesocorticolimbic pathway.13 The vulnerability to 
addiction development is frequently associated with genetic 
factors and personality traits. Recent studies highlighted that 
both alcohol-dependent and opiate-dependent patients have 
common genetic variants in dopamine D2 receptors and 
serotonin-transporter–linked promoter region associated 
with higher frequency to novelty-seeking personality traits.14 
Impulsivity, perhaps the most widely studied personality trait 
in the addiction literature, represents a predictor of future 
problems with substance use, due to its biologically-based 
link to additive core processes,15 and is closely associated 
with alcohol use, especially in individuals with poor working-
memory capacity.16
Personality disorders are considered the most important 
predictors of treatment outcome in drug abusers. Borderline 
personality disorder is associated with high lifetime rates 
of substance abuse as well as higher-than-expected rates 
of charges for various drug-related crimes and criminal 
behavior.17 The comorbidity between cocaine dependence 
and personality disorders from Clusters B and C is associ-
ated with executive-function deficits.18 The National Epi-
demiologic Survey on Alcohol and Related Conditions19 
highlighted that individuals with drug use disorder were 2.2 
times more likely to present a comorbid personality disorder. 
Some studies have identified the Cluster B antisocial and 
borderline personality disorders as most prevalent across 
various types of substance abusers.20,21
Many researchers found that individuals with dual 
diagnosis had high rates of a positive family history for 
substance use and/or psychiatric diseases, which could 
impact the severity and consequences of dual diagnosis.22,23 
Other studies evidenced that vulnerability to substance abuse 
increased among individuals with mental illness who were 
victimized during childhood24,25 and that this relationship 
induced a range of poor outcomes, including earlier onset and 
longer duration of substance abuse, worse physical health, 
and more interpersonal problems.26,27
The relationship between substance use and mental 
disorders has long been debated in order to evidence which 
of the two diseases could most condition the onset of the 
other. In adolescents and young adults with a first psychotic 
episode, co-occurring substance use was reported in 74% 
of all cases and was associated with limited response to 
treatment, decreased medication adherence, and worsened 
illness course.28,29 Psychosis and onset of substance use 
are often linked: one-third of patients experienced their 
first psychotic episode before the age of 19 years, and 
adolescence represents the peak time period for use and 
experimentation with alcohol, cannabis, and other illicit 
substances, the capability of which to induce psychotic 
symptoms has been well established.30–33 In particular, can-
nabis may represent a significant risk factor for the devel-
opment of psychotic illness in vulnerable individuals.30–34 
Schizophrenia patients have a higher risk for substance 
abuse due to degenerating cognitive abilities and disad-
vantageous life circumstances (“cumulative risk factor 
hypothesis”) or due to a need to reduce their symptoms 
and to offset the side effects of antipsychotic medication 
(“self-medication hypothesis”).35,36
The co-occurrence of mood and substance use disor-
ders is common and is clinically more severe and more 
difficult to treat, with considerable psychosocial disability 
and increased utilization of health care resources, including 
psychiatric hospitalizations.37–39 The lifetime prevalence 
rate of all bipolar disorders and substance use disorders is 
47.3% and, in particular, for bipolar I and substance use 
disorders is 60.3%.40–42 Comorbid substance use disorder is 
frequent in major depression, with lifetime rates of 40.3% 
for alcohol use and 17.2% for all other associated substance 
use disorders.43 Comorbidity between anxiety and substance 
use disorders is pervasive in the US population.43,44 Because 
mood symptoms may precede or be precipitated by drug and 
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alcohol  dependence, most authors hypothesize that common 
risk factors for both diseases, such as stressful events,45 
psychological trauma, and genetic vulnerability, could lead 
to co-occurring expression.46,47 
The aims of the current study were to analyze the clinical 
course, outcome complications, and assistance-care needs of 
a sample of dual-diagnosis patients treated by both the Mental 
Health Service (MHS) and the Substance Use Service (SUS) 
of Modena and Castelfranco Emilia, Italy, and to highlight 
which demographic, familial, premorbid, clinical, therapeu-
tic, rehabilitative, and/or nursing-care factors are related to 
dual diagnosis and can condition its course.
Methods
ethical considerations
This study, conducted in accordance with the principles of 
the Declaration of Helsinki and good clinical practice, was 
approved by the Human Subjects Review Committee of 
Azienda USL di Modena. Written informed consent was 
obtained from all participants at the beginning of treatments 
on both of the services after a discussion about treatment and 
utilization of their demographic and clinical data. 
sample
Our sample was chosen from all outpatients (N=175) with 
dual diagnosis (according to the International Classification 
of Diseases, 9th revision, Clinical Modification [ICD-9-
CM]48 in use in our department), treated by both MHS and 
SUS (catchment area of approximately 250,000 inhabitants) 
during the period January 1, 2012 to July 31, 2012. After 
excluding 30 dual-diagnosis patients treated by both services 
who voluntarily discontinued outpatient treatment during the 
study period (ie, did not return for subsequent appointments), 
our sample consisted of 145 dual-diagnosis patients. From 
the services’ medical records, we retrospectively collected 
demographic data and the variables shown in Table 1 for 
our sample. 
Variables
Familial and premorbid history
Family history of psychiatric disorders and/or substance 
abuse and stressful and/or negative events experienced during 
childhood or adolescence were analyzed in order to evaluate 
inherited or acquired predisposal conditions to dual-diagnosis 
development (Table 1).
clinical course
The following variables were chosen in order to identify 
the clinical complexity of the dual disorder: onset age of 
substance abuse and psychiatric illness, follow-up period of 
treatment at MHC and SUS, the kind of substance abused 
(both at the onset of illness and during the study period), 
number of psychiatric hospitalizations, psychiatric diagnoses 
according to the ICD-9-CM,48 psychopharmacological treat-
ments, therapies prescribed as substance replacement (eg, 
methadone, buprenorphine) and/or as an adversative drug 
(disulfiram), and psychotherapy method used (individual 
supportive, supportive group, or other kind) (Table 1).
Table 1 The variables collected in our sample
Familial and premorbid history Positive family history for psychiatric diseases and/or addiction
Significant loss (eg, parent bereavement, family financial ruin, family emigration), trauma 
(eg, abuse or maltreatment), severe organic diseases during childhood and adolescence
clinical course Onset age of substance use and psychiatric disorder
Kinds of onset and current substance(s) of abuse
Psychiatric diagnosis 
Follow-up period of Mental health service and substance Use service treatment 
Pharmacotherapy for psychiatric disorder and for substance abuse
Number of psychiatric hospitalizations
Psychotherapeutic activities
rehabilitative programs, social 
support, and professional staffing
Time (months) spent in therapeutic community or in psychiatric facilities
Social support (eg, protected job placement, house collocation, economic assistance)
Professional staffing: number of professionals involved in outpatient care
Outcome complications Family, economic, legal, and employment problems, health complications, 
self-destructive behaviors, social drift
clinical tests For severity: clinical global impression-severity administered at the beginning 
of psychiatric treatment
For improvement: clinical global impression-improvement administered during 
the period of this study
For functioning: global functioning assessment administered at the beginning 
of psychiatric treatment and during the period of this study
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rehabilitative programs, social support,  
and professional staffing
The rehabilitative programs were assessed through the 
months spent either in therapeutic communities or in 
psychiatric facilities. This represented, in our opinion, the 
time required to relearn the necessary basic skills to live 
autonomously. The social service activities consisted of all 
supportive interventions, such as protected job placement, 
house collocation, or economic assistance, required by 
patients due to their social maladaptive situation (Table 1). 
The level of nursing care was evaluated through the number 
of professionals involved in each patient’s treatment, since 
the complexity of care activities could range from drug 
administration or collection of samples for toxicological 
tests to more complex activities, such as educational and 
relational approaches for patients with severely impaired 
functioning (Table 1). 
Outcome complications
The following complications related to dual diagnosis were 
analyzed: work problems (eg, unemployment, frequent job 
change, economic crisis), family problems (eg, separation, 
family abandonment, loss of parental authority), health 
problems (eg, hepatitis C virus, HIV infection, alcoholic 
liver disease, epilepsy), legal problems (eg, revoked driving 
license, crimes related to substance use or psychiatric illness, 
detention in prison), self-injurious behavior (self-harm, 
suicide attempts, dangerous behavior), social problems (eg, 
isolation, institutional dependence, social drift, prostitution, 
homelessness) (Table 1).
clinical tests
In order to assess clinical and functional aspects of our 
sample, we collected the Global Impression Scale-Severity 
(CGI-S)49 and Global Assessment of Functioning (GAF)50 
scores collected during the first psychiatric evaluation 
at MHS and recorded in patients’ clinical charts. We 
asked the MHS psychiatrist of each dual-diagnosis patient 
to evaluate her/his clinical condition during the study 
period by means of the Clinical Global Impression Scale-
Improvement (CGI-I)48 and GAF, in order to compare it to 
the patients’ clinical situation at the first psychiatric treat-
ment (Table 1). 
statistical analysis
Data from the 145 patients in our final sample were sta-
tistically analyzed (descriptive statistics, Student’s t-test, 
chi-square test, Spearman correlations, simple and multiple 
linear and logistic regression, survival analyses) using the 
STATA software program.51
Results
Our sample included 95 males (65.52%) and 50 females 
(34.48%), with 94% Italians (n=136). The average age in our 
sample was 44 years for men and 45 years for women.
Familial and premorbid history
We were not able to obtain reliable information for 34% of 
our sample as no familial and/or premorbid elements of anam-
nesis had been reported in the medical records. We observed 
that most patients presented a premorbid history (Figure 1), 
including familial psychiatric illness or substance use (11%), 
stressful life events occurring in childhood or adolescence 
(23%), or both of these conditions (26%). We could not cor-
relate these factors with any other variables analyzed. Only 
6% of our patients did not report any premorbid factor.
clinical course
The mean ± standard deviation (SD) onset age of sub-
stance use disorders diagnosed according to ICD-9-CM48 
(24.83±10.06 years) was earlier than psychiatric illness onset 
age (30.47±12.10 years) and the difference between the two 
age groups was statistically significant (Student’s t-test, 
t=4.6441, df =128, P0.001). We evidenced that the positive 
correlation between the onset age of substance use and psy-
chiatric illness was statistically significant (Spearman’s rho 
=0.4522, P0.001; simple linear regression, standard error 
[SE] =0.0862, 95% confidence interval [CI] =0.3251–0.6662, 
df=128, P0.001). As shown in Figure 2, this trend was 
inverted during the last three decades of life, where psychi-
atric disease onset preceded substance use. 
Table 2 shows the onset age of pathological substance 
use, diagnosed according to ICD-9-CM.48 Onset age was 
statistically significantly related to the kind of abuse 
substance (simple linear regression, SE =0.3615, 95% 
CI =0.1865–1.6163, df=137, P0.05). As the survival 
analysis evidenced, the onset age of psychiatric diseases 
was conditioned by the kind of abuse substance (log-
rank test, hazard ratio [HR] =0.9078, SE =0.0408, 95% 
CI =0.8313–0.9914, df=137, P0.05), whereas the onset 
age of substance use was related to the time spent in thera-
peutic communities or psychiatric facilities (log-rank test, 
HR =1.1962, SE =0.1020, 95% CI =1.012–1.4140, df=119, 
P0.05) and to the follow-up period of psychiatric treatment 
in the MHS (log-rank test, HR =1.1399, SE =0.0304, 95% 
CI =1.0818–1.2011, df=119, P0.001).
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We did not find any statistically significant difference 
between substances used at the onset and those used during 
the study period, although the percentage of patients who 
used opiates was almost halved during the period of this 
study (Table 2).
We found that personality disorder was the most fre-
quent diagnosis (38.62%), followed by bipolar disorder and 
schizophrenic psychosis, each representing 21.38% of the 
sample (Table 3); psychiatric diagnosis was not statistically 
significant related to either a specific kind of substance use 
or a cocktail of substances. 
Sex was significantly correlated to psychiatric diagno-
ses (Pearson χ2=13.2134, df=144, P0.05): in our sample, 
schizophrenic psychosis was much more frequent in males 
(Table 3). Our male patients were more frequently treated 
with neuroleptic drugs (Pearson χ2=17.5814, df=144, 
P0.005) and more frequently presented familial, health, 
and social complications (Pearson χ2=19.3113, df=144, 
P0.005), whereas females more often presented self-
threatening behavior (Table 4).
The follow-up period (Table 5) of SUS treatment was sta-
tistically significantly correlated with the onset age of both psy-
chiatric diseases (multiple linear regression, SE =0.0648, 95% 
CI =0.0546–0.3113, df=120, P0.05) and addiction disorder 
(multiple linear regression, SE =0.0719, 95% CI =-0.4983 
to -0.2134, df=120, P0.001), whereas the follow-up period of 
MHS treatment (Table 5) was related only to the onset age of 
psychiatric diseases (multiple linear regression, SE =0.06367, 
95% CI =–0.2937 to -0.0416, df=125, P0.001).
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Figure 2 Onset age of psychiatric diseases and substance use.
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Figure 1 Familial and premorbid history of dual-diagnosis patients.
Neuropsychiatric Disease and Treatment 2014:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1484
Di lorenzo et al
rehabilitative programs, social support, 
and professional staffing
We found a statistically significant correlation between time 
spent in communities and/or in residential facilities (Table 5) 
and psychiatric diagnosis (multiple linear regression, 
SE =0.0964, 95% CI =0.0607–0.4420; df=144; P0.01), in 
particular for personality disorders (multiple linear regres-
sion, SE =0.8933; 95% CI =-0.1947 to -3.3376; df=144; 
P0.05), but not with a specific kind of substance. Most 
patients (77%) were involved in a rehabilitative or social 
program and 75% of patients were assisted by one (32%) or 
more nurses (43%) involved in their treatment (Table 5). 
Outcome complications
Only 33% of patients did not present any complications; 
the remaining 67% suffered from many different problems, 
in similar percentages, as shown in Table 4. As mentioned 
on page 5, 3rd paragraph, the kinds of problems were dif-
ferent for males and females. The occurrence of complica-
tions was statistically significantly related, with a positive 
Table 3 Psychiatric diagnosis, sex, and onset age of psychiatric diseases in our sample
Diagnosis (ICD-9-CM) Male, 
n
Female, 
n
Total, n (%) Onset age in 
years, mean ± SD
Organic psychotic conditions 
(290.0–294.0)
3 0 3 (2%) 44.00±1.00
schizophrenic disorders and 
other psychotic disorders
(295.0–295.9; 297.0–299.9)
27 4 31 (21%) 25.97±1.59
Bipolar disorders
(296.0–296.9)
16 15 31 (21%) 36.32±2.29
Neurotic disorders
(300.0–300.9)
12 6 18 (12%) 35.29±3.48
Personality disorders
(301.0–301.9)
32 24 56 (39%)
34 borderline 
8 paranoid
4 histrionic
2 narcissistic
2 dependent
2 avoidant
2 antisocial
2 Ns
27.83±1.58
Other disorders 5 1 6 (4%) 25.2±4.96
Total 95 50 145 (100%) 30.47±12.10
Abbreviations: ICD-9-CM, the International Classification of Diseases, 9th revision, Clinical Modification; n, number; NS, non specified; SD, standard deviation.
Table 2 Onset and current substance(s) of abuse and mean age of use onset per substance (n=145)
Substance of abuse Onset substance(s) 
of abuse
Current substance(s) 
of abuse
Onset age in years per 
substance, mean ± SD
Opiates 22.76% 13.10% 18.87±0.93
cocaine and amphetamines 4.14% 6.21% 23.83±2.62
cannabinoids 4.14% 4.14% 16.50±1.38
alcohol 31.72% 33.79% 31.41±1.65
cocktail of substances
Opiates, 30% 
Cocaine and amphetamines, 30%
Cannabinoids, 19%
Alcohol, 11%
Others, 10%
37.24% 33.79% 22.16±0.99
Total 100.00% 91.04%* 24.83±10.06
Notes: *8.96% of our patients were abstinent at the time of last clinical observation.
Abbreviation: sD, standard deviation.
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 correlation, both to the number of psychiatric hospitalizations 
(Spearman’s rho =0.1721, P0.05; multiple logistic regres-
sion, OR =1.7859, SE =0 .5061, 95% CI =1.0248–3.1121, 
df=106, P0.05) and to the number of professionals involved 
in each patient’s treatment (Spearman’s rho =0.2403, P0.005; 
multiple logistic regression, OR =4.3604, SE =2.6403, 95% 
CI =1.3307–14.2872, df=106, P0.05).
clinical tests
The mean ± SD GCI-S score (4.89±1.41) was statistically 
significantly related only to the kind of substance used, 
in particular alcohol (linear regression, SE =0.6270, 95% 
CI =0.0644–2.5490, df=118, P0.05) and cocktails of different 
substances (linear regression, SE =0.3484, 95% CI =0.2116–
1.5922, df=118, P0.05), as described in Table 2.
Table 4 complications and psychopharmacologic therapies in male and female patients 
Males, n Females, n Total, n (%)
complications
No complications 32 16 48 (33%)
Familial, employment, legal problems 21 7 28 (20%)
health problems 12 5 17 (12%)
self-threatening behavior 4 14 18 (12%)
social drift 13 2 15 (10%)
Other problems 13 6 19 (13%)
Total 95 50 145 (100%)
Psychopharmacologic therapies
Non pharmacologic therapy 7 6 13 (9%)
antipsychotics 18 2 20 (14%)
antidepressants 2 4 6 (4%)
Mood stabilizers 1 3 4 (3%)
Antipsychotics (long acting) 2 0 2 (1%)
Antipsychotics and other psychiatric drugs (but not antidepressants) 55 23 78 (54%)
Antidepressants and other psychiatric drugs (but not antipsychotics) 10 12 22 (15%)
Total 95 50 145 (100%)
Abbreviation: n, number.
Table 5 hospitalizations, community treatments, pharmacotherapies, rehabilitation, and nursing care in dual-diagnosis patients
Follow-up treatment years, mean ± SD (min–max)
at Mental health service 7.73±7.09 (1–35)
at substance Use service 8.83±7.59 (1–33)
Number of psychiatric hospitalizations per patient, mean ± SD (min–max) 1.77±1.31 (1 to 10)
Months spent in community or in residential facilities, mean ± SD (min–max) 1.03±1.56 (1 to 12)
Patients admitted to psychiatric ward at least once, n (%) 111 (76%)
Patients admitted to community or residential facilities at least once, n (%) 91 (62%)
Patients involved in psychotherapy activities, n (%) 
group, supportive, and other psychotherapies 94 (65%)
No psychotherapy activities 51 (35%)
Patients receiving pharmacological therapies for psychiatric disorders, n (%)
Psychiatric pharmacological therapy 132 (91%)
No pharmacological therapy 13 (9%)
Patients receiving pharmacological therapies for substance use, n (%)
Pharmacological therapy 63 (43%)
No pharmacological therapy 82 (57%)
Patients involved in rehabilitative programs and social support, n (%)
rehabilitative programs, social support, protected employment 112 (77%)
No rehabilitative programs, social support, or protected employment 33 (23%)
Patients per corresponding number of professionals involved in their treatment, n (%) 
No professionals 37 (25%)
One professional 46 (32%)
Two or more professionals 62 (43%)
Abbreviations: max, maximum; min, minimum; n, number; sD, standard deviation.
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The mean ± SD GCI-I score (3.51±1.53) was statistically 
significantly related only to psychotherapy activities, par-
ticularly to group psychotherapy (multiple linear regression, 
SE =0.5759, 95% CI =-2.7887 to -0.4957, df=97, P0.05).
The mean ± SD GAF score obtained during the study 
period (56.42±20.67) was statistically significantly differ-
ent from the mean GAF score at the beginning of psychi-
atric treatment (44.44±18.82) (Student’s t-test, t=-7.0467, 
df=251, P0.001) and was statistically significantly related 
to the number of psychiatric hospitalizations (multiple linear 
regression, SE =1.8065, 95% CI =-7.882164 to -0.6933576, 
df=97, P0.05), with a negative correlation (Spearman’s 
rho =-0.2106, P0.05). 
Discussion
The higher frequency of male patients in our sample cor-
responds to the sex distribution in the SUS (71% males and 
29% females), but our dual-diagnosis patients were older 
on average (44 years) than all other patients of the SUS 
(36 years), suggesting that the occurrence of dual diagnosis 
needed many years to develop completely.
In accordance with most recent studies,25,52 we noticed 
a high prevalence of psychiatric illness and/or addiction 
disorders in the family histories of our patients and a much 
higher occurrence of multiple stressful life events during 
their childhood and adolescence, which could represent a 
sort of inherited or acquired vulnerability to the development 
of both diseases. 
Because substance use preceded psychiatric disease in 
our sample, we could infer that addiction represents the 
pathological factor that had strongly conditioned mental 
disease development, but we have to underline, in accordance 
with the literature,10 that a preclinical stage of psychiatric 
disorders, not recorded in medical charts, could have made 
people more vulnerable to drug abuse or have induced them 
to use substances as a sort of self-therapy. Nevertheless, the 
two disorder onsets were so tightly interconnected as to lead 
us to hypothesize common risk factors for both diseases. In 
particular, the kind of substance abuse conditioned the onset 
age of psychiatric and addiction disorders, as most authors 
have already evidenced:12,53 alcohol abuse began later and 
was most often related to psychiatric disorder development, 
whereas cannabis use was closely related to younger age and, 
probably, to psychosis onset. On the other hand, the chronic-
ity and severity of psychiatric diseases affected addiction 
development, which could induce a sort of social drift. The 
patients suffering from Cluster B personality disorders, which 
was the most frequent psychiatric diagnosis as also reported 
by other studies,54,55 spent a longer time than other patients 
either in psychiatric communities or residential facilities, 
probably because of their greater difficulties in social and 
relational adaptation.
Our sample included “severely ill” patients as attested to 
by both the high percentage (76%, as shown in Table 5) of 
patients admitted at least once to a psychiatric hospital during 
the illness course observed and the CGI-S mean score, which 
was in turn conditioned by the kind of abuse substance, in 
particular by alcohol. The indicators of our patients’ severity 
were represented by the frequent psychiatric hospitalizations, 
the presence of several complications, and the high number 
of professionals involved in the treatment of each patient.
The complications observed were different in males and 
females: familial, economic, and social maladaptive situ-
ation with legal problems were higher in males, whereas 
females were more vulnerable to self-threatening behaviors 
and depressive conditions, as the more frequent prescription 
of antidepressant drugs evidenced. Moreover, males were 
more frequently treated with antipsychotic drugs, probably 
due to altered behavior as well as to the higher number of 
male schizophrenia patients. These observations led us to 
infer a different evolution of dual diagnosis: an antisocial 
drift in male patients and a depressive course in female 
patients.
Outpatient services had to provide long-term supportive 
therapies, which were conditioned in both services by the 
onset age of substance use. This data further suggests that 
dual diagnosis represented a negative prognostic factor 
because it induced chronicity and reduced the efficacy of 
therapeutic programs.
We observed that approximately 65% of patients in our 
sample were involved in psychotherapy activities, which 
were related to improvement assessed by the CGI-I scale. In 
spite of the chronic course of illness and the complications 
recorded, the final GAF scale scores were statistically signifi-
cantly higher than the initial ones, suggesting that patients’ 
functioning had improved after long-term treatment. 
Conclusion
The course of dual diagnosis in our sample was chronic, 
severe, and disabling and required many long-term therapeutic 
and rehabilitative programs to deal with various disabilities. 
Health professionals involved in therapy, assistance, and 
rehabilitation of dual-diagnosis patients should clearly keep 
in mind the relationship between substance abuse and mental 
disorder in order to focus on screening tools, damage-reducing 
interventions, and continuous assistance/support.
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advantages and limits
Our study, although limited by its retrospective design, high-
lighted a sample of patients representative of both Mental 
Health Service and Substance Use Service populations over 
a relatively long follow-up period. The sample was selective 
since it contained only those in treatment and cannot neces-
sarily be generalized to other populations of dual-diagnosis 
patients. The variables collected were not exhaustive, but 
sufficiently representative of dual-diagnosis clinical issues. 
implications for future
Additional studies are necessary to better explore dual-
diagnosis topics. In particular, both of the conditions fos-
tering the development of dual diagnosis and its long-term 
follow-up, differentiated for kind of abuse substance and 
type of psychiatric disease, should be investigated in larger 
and more-focused samples in order to identify the patients’ 
vulnerabilities and to improve treatment programs.
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